By Mark Roskey, Vice President and General Manager, Applications and Reagents
The human genome encodes thousands of secreted proteins, each of which is an actor in the delicate biochemical balance of diagnostics. Even a slight change in any one of these proteins can mean the difference between sickness and health. Such a change also provides a critical window into the body and helps to direct diagnosis and treatment, however, the vast majority of secreted proteins are present in concentrations well below what conventional technologies can measure, and their role in human health is poorly understood. Researchers have continued to seek ways to detect and diagnose earlier and more accurately through protein detection, and have been unsuccessful at doing so – until now.
Efficient and Cost-Effective Removal Of Residual Endotoxin
Endotoxin or lipopolysaccharides (LPS) are highly toxic components of the cell wall of Gram-negative bacteria and are often present in significant amounts in bacterial cell culture expression systems such as E. coli. By Ben Galarza, Jason Shipp, Buzz Lobbezoo, Jennie Walden and Steve Burton, ProMetic BioSciences Ltd
Hamilton Robotics Launches Highly Flexible PCR Setup Workstation
Hamilton Robotics introduces the PCR setup STARlet, the first automated liquid handling system flexible enough to accommodate any DNA amplification reagent kit, from simple setups and small budgets to highly demanding workflows.
BioReliance Acquires Rights To Big Blue Colonies And Cell Lines From Agilent
Sigma-Aldrich Corporation recently announced that BioReliance, the biologics and early development services business under SAFC, has signed an agreement to acquire the colonies required for the Big Blue transgenic rodent mutation (TRM) assay and to obtain a license to its associated trademark from Agilent Technologies.
WHITE PAPERS & CASE STUDIES
Significantly Improve FoxP3 Staining In Human Whole Blood
Regulatory T-cells (Treg) play an essential role in the control of immune responses to self and foreign antigens maintaining the balance between immunity and tolerance.
Discovery Of Biochemical Markers For Understanding Disease
'Omic technologies and systems biology research provide a comprehensive view of the genetic, protein and biochemical nature of disease.
How To Analyze Nuclear Stained Cells Using A Multi-Mode Microplate Reader With DAPI-Stained Cells
The imaging and analysis of fluorescently stained cells has traditionally been accomplished using manual microscopic methods with low numbers of samples, while the analysis of higher sample numbers requires the use of very expensive dedicated microscopes.
PRODUCTS & SERVICESMore Products & Services
DOWNSTREAM ASSAYS MEDIAMore Downstream Assays Media
DOWNSTREAM ASSAYS NEWS
The Michael J. Fox Foundation Launches New Funding Opportunities For Parkinson's Research
The Michael J. Fox Foundation (MJFF) is today announcing the launch of four new funding programs focused on driving forward research toward transformative treatments and a cure for Parkinson's disease (PD).
Improving The Validity Of High Throughput Screening Assays
Artel is launching the first in a new line of 100% DMSO-based Sample Solutions for use with the MVS® Multichannel Verification System. These will provide users with the ability to measure the accuracy and precision of volumes of DMSO dispensed into microwell plates.
Cell Therapeutics Begins Enrollment In Phase 3 PERSIST-1 Trial Of Pacritinib For The Treatment Of Myelofibrosis
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis.
Ambit Biosciences Completes $50M Financing To Advance Lead Drug Candidate In Acute Myeloid Leukemia
Ambit Biosciences Inc. today announced that the company has closed the first $25 million tranche of a new $50 million preferred stock financing to support continued advancement of its lead drug candidate, quizartinib.
SAGE® Labs, Ekam Imaging, Inc. Partner To Develop Preclinical Imaging Assays To Screen Therapies Of Neurodegenerative Disease
Sigma-Aldrich® Corporation (Nasdaq: SIAL) today announced that Sigma Advanced Genetic Engineering (SAGE) Labs, an initiative of Sigma®Life Science, and Ekam Imaging, Inc. have partnered to develop a suite of preclinical services based on the advanced translational power of genetically engineered rat models from SAGE Labs and Ekam's expertise in functional magnetic resonance imaging (fMRI) technology. For more information on SAGE Labs, visit www.sageresearchmodels.com
FDA Inspects MicroConstants For Compliance With Good Laboratory Practices, No Deficiencies Noted
Bioanalytical and pharmacokinetic specialty Contract Research Organization (CRO) MicroConstants announced today the successful completion of a five-day inspection by the United States Food and Drug Administration (FDA) for compliance with Good Laboratory Practice (GLP) regulations.
New Molecular Assay Allows Healthcare Facilities To Simplify Active Surveillance Testing for Deadly Superbug
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), today announced that the new BD MAX™ MRSA molecular test has received a Moderate Complexity rating under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). Performed on the fully-automated BD MAX™ System, the assay is designed to rapidly and accurately identify patients colonized with methicillin-resistant Staphylococcus aureus (MRSA).
Absorption Systems Announces Novel Test Platform For Interactions With The BCRP Transporter
Absorption Systems, a world leader in developing novel test systems for drug transporters, announces the availability of a long-awaited assay platform for the human BCRP transporter, also known as breast cancer resistance protein.
EntreMed Announces Initiation Of Phase 2 Trial In Triple-Negative Breast Cancer
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study.